Overview

ChemoCentryx has established one of the broadest chemokine-based therapeutics pipelines in the biopharmaceutical industry. We are internally discovering and developing several clinical- or preclinical-stage programs, each targeting distinct chemokine receptors with different small molecule compounds. Our compounds are designed to be highly potent, to minimize off-target side effects as much as possible and to be orally-available for improved patient compliance, as well as ease and efficiency of manufacture.

* Subject to our strategic alliance with GSK

Our lead product candidate, Traficet-EN™ (CCX282), targeting the CCR9 chemokine receptor, is in a Phase II/III clinical trial for the treatment of patients with moderate-to-severe Crohn's disease as well as in a Phase II clinical trial for the treatment of patients with celiac disease. A second product candidate, CCX140, which targets the CCR2 chemokine receptor, is in a Phase I single-dose escalation trial. In addition, we have four programs, currently in the lead optimization stage, targeting chemokine receptors and chemoattractant receptors.

^ Return to Top